Roche plans investment in the expansion of its logistics centre in Kaiseraugst

Basel, 03 March 2011

Total investment of around 35 million Swiss francs

Roche announced today that it has applied to the local authorities in Kaiseraugst for planning permission to expand its logistics centre. The company intends to expand its existing centre in response to growing global demand for the company’s biotech medicines, such as Actemra, Avastin, Herceptin, MabThera and Pegasys, which have to be produced and stored under refrigerated conditions. The expansion will involve investments of around CHF 35 million.

“The planned investments in the logistics centre are a further clear indication of the location’s importance within the Roche Group”, explained Matthias M. Baltisberger, Head of the Basel site. “The building will satisfy all the logistical requirements for handling modern medicines and will comply with the strictest energy-efficiency standards.”

Preparatory work is expected to start in the second quarter of 2011 once planning permission has been granted by the Kaiseraugst local authorities. Medicines will then be stored, packaged and shipped from the new extension from the start of 2013.

The new Roche logistics centre in Kaiseraugst

One of the most up-to-date warehousing and logistics centres in Europe was completed in Kaiseraugst in 1995. The existing Roche warehousing and logistics centre currently supplies more than 130 countries with medicines. The company is planning to add further refrigerated areas to this centre in response to rising volumes. Roche will be able to benefit in full from synergies with the existing infrastructure while guaranteeing an integrated supply chain.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. Additional information: www.roche.com.